Skip to main content
Premium Trial:

Request an Annual Quote

Epidauros Licenses Drug Metabolism Biomarker to Osmetech to Push Into PGx

NEW YORK (GenomeWeb News) — Osmetech will use Epidauros Biotechnologies’ CYP450 2D6 biomarker patent to expand into pharmacogenomics testing, the companies said today.
 
The diagnostic healthcare company has signed a non-exclusive licensing agreement to use the IP to the genetic variant 2988G>A, which it will use in combination with other variants as predictive markers in its molecular and critical care diagnostic ventures.
 
Financial details were not disclosed.
 
Epidauros, a German pharmacogenomics services company, entered into a similar licensing agreement with the same biomarker with Bioscience Corp this spring for services concerning. That deal included an up-front signing fee and royalties.  
 
Osmetech, based in Pasadena, Calif., currently has a cystic fibrosis product on the market and plans to make its e-Sensor platform its first entry into pharmacogenomics.